You searched for "diabetes"

550 results found

Two-year interim safety results of the 0.2ug/day FAC intravitreal implant for the treatment of DMO

This is a 24-month interim prospective observational study of 95 previously steroid challenged patients (115 eyes) receiving intravitreal 0.2ug/day fluocinolone acetaid (FAC) implant for diabetic macular oedema (DMO) treatment. The mean IOP for pre- and post- FAC implants were stable,...

Posterior capsular rupture risk factors as reported in the European registry

In this cross-sectional review of the European Registry of Quality Outcomes for Cataract and Refractive Surgery (EUREQUO) including 2,853,376 patients and 31,749 cases with posterior capsular rupture (PCR), the authors observed a trend of reduction in PCR rate from 1.44%...

Bromfenac versus betamethasone in diabetic macular oedema

This is a randomised, prospective, single-centre trial in patients diagnosed with diabetic macular oedema (DMO) with central subfield thickness (CST) of 250-500µm, who refused anti-VEGF treatment. Nineteen eyes of 19 patients were randomised to bromfenac (BF) or betamethasone (BM) drops,...

The compendium to clinical evidence in DMO treatment

This review article summarises the current evidence base in the treatment options for diabetic macular oedema (DMO). The authors have included many real-world data studies that provided valuable insights into the optimal management of DMO. The authors argue that these...

Virtual COVID clinics

The clinics at Ystradgynlais Community Hospital are a little different of late. The nurses are still there, I still get tea with custard creams and the letters I dictate are still all written up by the next day. But there...

Macula re-attachment following intravitreal ranibizumab in rhegmatogenous retinal detachment

Ranibizumab (Lucentis) is a vascular endothelial growth factor inhibitor (anti-VEGF) used for treatment of choroidal neovascular membrane [1]. We report a case where macula off inferior rhegmatogenous retinal detachment was misdiagnosed as wet age-related macular degeneration (AMD) and three intravitreal...

A case of ‘60-day glaucoma’

Neovascular glaucoma (NVG) has been called ‘90-’ or ‘100-day glaucoma’ in the past due to its typical development three months after the onset of central retinal vein occlusion (CRVO). In reality, NVG can occur anywhere between two weeks and two...

Insights on medical AI for ophthalmology: an update on current perspectives

Artificial intelligence (AI) has immense promise for revolutionising medical practice. Generative AI is a form of AI in which algorithms are trained on datasets that can be used to generate new content, such as text, images or video based on...

Patients use their own blood to treat dry eye symptoms

Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’? Headline: Patients use their own blood to treat dry eye symptoms Grossman first described the technique of...

The power of the full blood count

Vishal Shah walks us through his thought process whilst highlighting the importance of routine investigations when dealing with unusual retinovascular presentations. Retinal changes can arise in anaemia, leukaemia, lymphoma, myeloproliferative and myelodysplastic syndrome. They are often the first manifestation of...

Glaucoma UK urges people to get their eyes tested amidst rise in glaucoma cases

With the number of people living with glaucoma in the UK expected to increase by almost a third between 2020 and 2035, Glaucoma UK is urging people to get their eyes tested.

Transforming eyecare with AI at 100% Optical

“We are drowning in people we need to see in hospital eye services, and some people are going blind as a result. We are looking at nearly 10m hospital appointments for ophthalmology a year, with an approximately 33% increase over...